Petros Pharmaceuticals CFO Arnold departs; Robert Weinstein appointed as CAO/PFO

Petros Pharmaceuticals, Inc.

Mitchell Arnold mutually separated as VP Finance, Principal Financial & Accounting Officer, effective June 18, 2026.
Robert Weinstein appointed as Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer, effective immediately.
Separation includes $38,500 severance (2 months salary), accelerated vesting of 3,000 unvested shares, and 2 months COBRA premium subsidy.
Weinstein brings 30+ years experience; most recently CFO of TAO Synergies (formerly Synaptogenix) since 2013.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert Weinstein

Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer

PTPI · Petros Pharmaceuticals, Inc.

Effective: 2026-06-18
Filed: June 18, 2026, 5:14 PM ET

On June 18, 2026, the board of directors (the “Board”) of the Company appointed Robert Weinstein to the positions of Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective immediately.

Departed

Mitchell Arnold

Vice President of Finance, Principal Accounting Officer and Principal Financial Officer

PTPI · Petros Pharmaceuticals, Inc.

Effective: 2026-06-18
Successor: Robert Weinstein
Filed: June 18, 2026, 5:14 PM ET

On June 18, 2026, Petros Pharmaceuticals, Inc. (the “Company”) and Mitchell Arnold, who served as the Company’s Vice President of Finance, Principal Accounting Officer and Principal Financial Officer, mutually agreed to the separation of Mr. Arnold from such roles, effective as of June 18, 2026

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Weinstein was appointed as Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer at Petros Pharmaceuticals, Inc..

Action: appointed
Role: Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer

Exact text from the filing

On June 18, 2026, the board of directors (the “Board”) of the Company appointed Robert Weinstein to the positions of Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mitchell Arnold departed as Vice President of Finance, Principal Accounting Officer and Principal Financial Officer at Petros Pharmaceuticals, Inc..

Action: separated
Role: Vice President of Finance, Principal Accounting Officer and Principal Financial Officer

Exact text from the filing

On June 18, 2026, Petros Pharmaceuticals, Inc. (the “Company”) and Mitchell Arnold, who served as the Company’s Vice President of Finance, Principal Accounting Officer and Principal Financial Officer, mutually agreed to the separation of Mr. Arnold from such roles, effective as of June 18, 2026

View on SEC.gov

Petros Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-075849

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.